GABA Transport Mechanisms in Neurological Disorders

Gamma-aminobutyric acid (GABA) transporters are integral membrane proteins that govern the termination of inhibitory synaptic transmission and regulate neuronal excitability. Belonging to the solute carrier 6 family, the principal subtypes (GAT1–4 and BGT1) couple the co-transport of sodium and chloride ions to GABA uptake, ensuring rapid clearance from the synaptic cleft. Dysregulation of these transporters has been implicated in the pathophysiology of epilepsy, Parkinson’s disease, mood disorders and neuropathic pain. Recent discoveries have revealed that transporter localisation extends beyond neurons to astrocytes, oligodendrocytes and microglia, broadening our understanding of glial-neuronal interplay in health and disease. Advances in structural biology and pharmacology have delineated key binding interactions and conformational states, guiding the design of selective inhibitors that show promise for seizure control, analgesia and modulation of inhibitory tone without the liabilities of non-selective agents.

Research from Nature Portfolio

Recent studies have characterised substrate-inhibitors targeting the betaine/GABA transporter subtype, revealing how non-conserved residues and ligand flexibility govern subtype-selectivity. A series of cyclised analogues was synthesised and shown to act at the orthosteric site of the transporter, with in silico-directed mutagenesis identifying key amino acids that mediate binding affinity and selectivity. These findings provide a structural framework for rational design of high-precision tools to probe the elusive role of the betaine/GABA transporter in neural and peripheral tissues, setting the stage for future drug-discovery endeavours.

GABA Transport Mechanisms in Neurological Disorders publication trend

The graph below shows the total number of articles in gaba transport mechanisms in neurological disorders across all publications each year (not limited to Nature Index journals).

Technical terms

GABA: γ-Aminobutyric acid, the principal inhibitory neurotransmitter in the mature central nervous system, modulating neuronal excitability.

GABA transporter (GAT): A sodium- and chloride-dependent membrane protein that clears GABA from the synaptic cleft; includes multiple subtypes (GAT1–4 and BGT1) with distinct tissue distributions.

Orthosteric site: The primary substrate-binding pocket of a transporter or receptor where endogenous ligands interact.

Substrate-inhibitor: A compound that mimics the natural substrate of a transporter, binding to its active site to block normal transport without being translocated.

Subtype-selectivity: The characteristic of a compound to preferentially interact with one transporter isoform over others, reducing off-target effects.

References

1. γ-Aminobutyric acid transporters as relevant biological target: Their function, structure, inhibitors and role in the therapy of different diseases. International Journal of Biological Macromolecules (2020).
2. Exploring the molecular determinants for subtype-selectivity of 2-amino-1,4,5,6-tetrahydropyrimidine-5-carboxylic acid analogs as betaine/GABA transporter 1 (BGT1) substrate-inhibitors. Scientific Reports (2020).
3. Pharmacological Characterization of a Betaine/GABA Transporter 1 (BGT1) Inhibitor Displaying an Unusual Biphasic Inhibition Profile and Anti-seizure Effects. Neurochemical Research (2020).
4. Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity. ACS Chemical Neuroscience (2021).